Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + vinorelbine + capecitabine for HER2-negative advanced breast cancer
ChiCTR2400090102Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, vinorelbine and capecitabine in breast cancer, sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
tucidinostatvinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400090102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090102.